Surgical delay and mortality for primary cutaneous melanoma - 10/03/21
Doi : 10.1016/j.jaad.2020.07.078
Samantha Guhan, BA a, Genevieve Boland, MD, PhD b, Kenneth Tanabe, MD b, William Lin, MD c, Bobby Reddy, MD c, Elena B. Hawryluk, MD, PhD c, Arthur J. Sober, MD c, Hensin Tsao, MD, PhD c, ⁎ 
a Harvard Medical School, Boston, Massachusetts
b Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
c Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
∗Correspondence to: Hensin Tsao, MD, PhD, Massachusetts General Hospital, Edwards 211, 50 Blossom St, Boston, MA 02114Massachusetts General HospitalEdwards 211, 50 Blossom StBostonMA02114
| Funding sources: None. |
|
| Conflicts of interest: None disclosed. |
|
| IRB approval status: Not applicable. |
|
| Reprints not available from the authors. |
© 2020
Pubblicato da Elsevier Masson SAS.
Vol 84 - N° 4
P. 1089-1091 - aprile 2021 Ritorno al numero
Articolo precedente
- Identification of potential inhibitors targeting BRAF-V600E mutant melanoma cells
- Onat Kadioglu, Mohamed E.M. Saeed, Henry J. Greten, Katharina Mayr, David Schrama, Wynand P. Roos, Thomas Efferth
- Mycophenolate mofetil for the treatment of cutaneous lichen planus: A retrospective case series
- Matthew L. Hrin, Arjun M. Bashyam, William W. Huang, Steven R. Feldman
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?